Literature DB >> 19925894

Gene expression profile in osteoclasts from patients with Paget's disease of bone.

Laetitia Michou1, Estelle Chamoux, Julie Couture, Jean Morissette, Jacques P Brown, Sophie Roux.   

Abstract

Paget's disease of bone (PDB) is a common metabolic bone disorder with a significant genetic component. To date, only one gene associated with PDB has been identified, the p62-Sequestosome1 gene (SQSTM1), and more than 20 mutations of this gene have been reported in PDB, the most common being the P392L substitution. In order to search for differentially expressed genes in PDB, we investigated the relative gene expression profile of candidate genes in osteoclast (OCL) cultures from 12 PDB patients and six unmatched healthy controls with known genetic status regarding p62, including healthy carriers of the P392L mutation. We selected 48 OCL-expressed candidate genes that may be involved in relevant pathways of PDB pathogenesis, such as OCL signaling, survival, bone resorption activity, or adhesion. In OCL cultures derived from peripheral blood mononuclear cells, total RNA extraction was performed, followed by real-time PCR experiments. Relative quantification analysis utilized the qBase method where relative expression levels were normalized with respect to a set of reference primer pairs for three housekeeping genes. When compared to non-mutated healthy controls, OCL cultures from PDB patients displayed a significant down-regulation in genes involved in apoptosis (CASP3 and TNFRSF10A), in cell signaling (TNFRSF11A), in the OCL bone resorbing function (ACP5 and CTSK) and in the gene coding for Tau protein (MAPT) (all comparisons, p<0.0001). Comparison of relative gene expression in PDB patients with P392L mutation versus PDB patients without SQSTM1 mutation did not provide significant differential gene expression. However, we observed a non-significant decrease in the expression of several genes such as IL6ST, HIF1A, OSTM1, TNFRSF-10B and -10D, PDK1, MAPT and CASP3 in healthy carriers of the P392L mutation. These results provide important information about the mis-regulated activities of pagetic OCL, and highlight the role of altered apoptosis pathways in these cells. They also suggest that the SQSTM1 P392L mutation plays a role in PDB pathogenesis, even at early preclinical stages in healthy carriers of the P392L mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925894      PMCID: PMC5224937          DOI: 10.1016/j.bone.2009.11.012

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  27 in total

1.  1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.

Authors:  C Menaa; J Barsony; S V Reddy; J Cornish; T Cundy; G D Roodman
Journal:  J Bone Miner Res       Date:  2000-02       Impact factor: 6.741

Review 2.  Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.

Authors:  Michael P Whyte
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

3.  Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation.

Authors:  Jeganathan Ramesh Babu; Thangiah Geetha; Marie W Wooten
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

4.  Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations.

Authors:  James R Cavey; Stuart H Ralston; Lynne J Hocking; Paul W Sheppard; Barbara Ciani; Mark S Searle; Robert Layfield
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

5.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.

Authors:  Nancy Laurin; Jacques P Brown; Jean Morissette; Vincent Raymond
Journal:  Am J Hum Genet       Date:  2002-04-30       Impact factor: 11.025

6.  Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.

Authors:  C Menaa; S V Reddy; N Kurihara; H Maeda; D Anderson; T Cundy; J Cornish; F R Singer; J M Bruder; G D Roodman
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone.

Authors:  Dorit Naot; Usha Bava; Brya Matthews; Karen E Callon; Gregory D Gamble; Michael Black; Sarah Song; Rocco P Pitto; Tim Cundy; Jill Cornish; Ian R Reid
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

8.  Apoptotic gene expression in Paget's disease: a possible role for Bcl-2.

Authors:  Craig P Brandwood; Judith A Hoyland; M Chantal Hillarby; Jacqueline L Berry; Michael Davies; Peter L Selby; Andrew P Mee
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

9.  Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.

Authors:  Nicolas Houde; Estelle Chamoux; Martine Bisson; Sophie Roux
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

Review 10.  Novel osteoclast signaling mechanisms.

Authors:  Masahiro Shinohara; Hiroshi Takayanagi
Journal:  Curr Osteoporos Rep       Date:  2007-06       Impact factor: 5.096

View more
  9 in total

1.  TRPV-5 mediates a receptor activator of NF-kappaB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption.

Authors:  Estelle Chamoux; Martine Bisson; Marcel Daniel Payet; Sophie Roux
Journal:  J Biol Chem       Date:  2010-06-11       Impact factor: 5.157

2.  CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.

Authors:  Peng Xue; Xiangxiang Hu; James Powers; Nicole Nay; Emily Chang; Jane Kwon; Sing Wai Wong; Lichi Han; Tai-Hsien Wu; Dong-Joon Lee; Henry Tseng; Ching-Chang Ko
Journal:  Biochem Biophys Res Commun       Date:  2019-02-27       Impact factor: 3.575

3.  Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone.

Authors:  Kumaran Sundaram; Srinivasan Shanmugarajan; D Sudhaker Rao; Sakamuri V Reddy
Journal:  Endocrinology       Date:  2011-08-30       Impact factor: 4.736

Review 4.  Disorders of bone remodeling.

Authors:  Xu Feng; Jay M McDonald
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 5.  Emerging strategies and therapies for treatment of Paget's disease of bone.

Authors:  Laëtitia Michou; Jacques P Brown
Journal:  Drug Des Devel Ther       Date:  2011-04-26       Impact factor: 4.162

6.  Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology.

Authors:  Amélie E Coudert; Andrea Del Fattore; Céline Baulard; Robert Olaso; Corinne Schiltz; Corinne Collet; Anna Teti; Marie-Christine de Vernejoul
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

7.  miR profile in pagetic osteoclasts: from large-scale sequencing to gene expression study.

Authors:  Hoang Dong Nguyen; Martine Bisson; Michelle Scott; Gilles Boire; Luigi Bouchard; Sophie Roux
Journal:  J Mol Med (Berl)       Date:  2021-10-05       Impact factor: 4.599

8.  The adaptor protein p62/SQSTM1 in osteoclast signaling pathways.

Authors:  Stephen McManus; Sophie Roux
Journal:  J Mol Signal       Date:  2012-01-04

9.  Alternative splicing in osteoclasts and Paget's disease of bone.

Authors:  Roscoe Klinck; Gino Laberge; Martine Bisson; Stephen McManus; Laëtitia Michou; Jacques P Brown; Sophie Roux
Journal:  BMC Med Genet       Date:  2014-08-14       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.